BAF312 (Siponimod) (Synonyms: BAF312) |
| رقم الكتالوجGC17201 |
BAF312 (Siponimod) (BAF-312) هو مُعدِّل مستقبلات سفينجوزين انتقائي نشط عن طريق الفم وانتقائي (S1P).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1230487-00-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BAF312 is a potent and selective agonist of S1P with EC50 value of 0.39nM for S1P1 receptors and 0.98nM for S1P5 receptors, respectively [1].
BAF312 has shown >1000-fold selectivity for S1P1 versus S1P2, S1P3 and S1P4 receptors [1]. In vitro metabolism studies with liver microsomes have shown that the metabolic clearance of BAF312 is high in rat, low to moderate in monkey and human being, and low in dog and mouse. Moreover, BAF312 has been revealed to dose-dependently reduce peripheral lymphocyte counts in Lewis rats [2].
.
References:
[1] Gergely P1, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, Pan S, Gray NS, Hinterding K, Cooke NG, Groenewegen A, Vitaliti A, Sing T, Luttringer O, Yang J, Gardin A, Wang N, Crumb WJ Jr, Saltzman M, Rosenberg M, Wallström E. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012 Nov;167(5):1035-47.
[2] Pan S1, Gray NS1, Gao W1, Mi Y1, Fan Y1, Wang X1, Tuntland T1, Che J1, Lefebvre S1, Chen Y1, Chu A1, Hinterding K2, Gardin A2, End P2, Heining P2, Bruns C2, Cooke NG2, Nuesslein-Hildesheim B2 .Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013 Jan 4;4(3):333-7.
.
| Cell experiment [1]: | |
|
Cell lines |
human atrial myocytes |
|
Preparation method |
This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0.001-1000 nM |
|
Applications |
In human atrial myocytes, BAF312 concentration-dependently increased GIRK current amplitude with EC50 value of 15.8 nM and reached approximately 80% of the carbachol-induced maximal current activation. |
| Animal experiment [1, 2]: | |
|
Animal models |
rat experimental autoimmune encephalomyelitis (EAE) model; Lewis rats |
|
Dosage form |
0.03, 0.3 or 3 mg/kg, orally administrated, 24 day; 1 mg/kg, orally administrated |
|
Application |
In rat experimental autoimmune encephalomyelitis (EAE) model, BAF312 starting on day 11 significantly inhibited established neurological deficits. BAF312 at 0.3 or 3 mg/kg caused a significant reduction of disease scores (AUC (area under the concentration–time curve) from days 12 to 34). In Lewis rats, BAF312 (Siponimod) (1 mg/kg) dose-dependently reduced peripheral lymphocyte counts. At the Tmax of 8 h postadministration, the lymphocyte counts were decreased by 88%. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Gergely P1, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, Pan S, Gray NS, Hinterding K, Cooke NG, Groenewegen A, Vitaliti A, Sing T, Luttringer O, Yang J, Gardin A, Wang N, Crumb WJ Jr, Saltzman M, Rosenberg M, Wallstrm E. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012 Nov;167(5):1035-47. [2] Pan S1, Gray NS1, Gao W1, Mi Y1, Fan Y1, Wang X1, Tuntland T1, Che J1, Lefebvre S1, Chen Y1, Chu A1, Hinterding K2, Gardin A2, End P2, Heining P2, Bruns C2, Cooke NG2, Nuesslein-Hildesheim B2 .Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013 Jan 4;4(3):333-7. | |
| Cas No. | 1230487-00-9 | SDF | |
| المرادفات | BAF312 | ||
| Chemical Name | 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid | ||
| Canonical SMILES | CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O | ||
| Formula | C29H35F3N2O3 | M.Wt | 516.6 |
| الذوبان | ≥ 194.8mg/mL in DMSO | Storage | Store at -20° C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9357 mL | 9.6787 mL | 19.3573 mL |
| 5 mM | 0.3871 mL | 1.9357 mL | 3.8715 mL |
| 10 mM | 0.1936 mL | 0.9679 mL | 1.9357 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *